Unmet medical needs and future perspectives for leiomyosarcoma patients—A position paper from the national leiomyosarcoma foundation (NLMSF) and sarcoma patients euronet (SPAEN)

Bernd Kasper, Annie Achee, Kathrin Schuster, Roger Wilson, Gerard van Oortmerssen, Rebecca A. Gladdy, Matthew L. Hemming, Paul Huang, Matthew Ingham, Robin L. Jones, Seth M. Pollack, Denise Reinke, Roberta Sanfilippo, Scott M. Schuetze, Neeta Somaiah, Brian A. Van Tine, Breelyn Wilky, Scott Okuno, Jonathan Trent

Research output: Contribution to journalReview articlepeer-review

Abstract

As leiomyosarcoma patients are challenged by the development of metastatic disease, effective systemic therapies are the cornerstone of outcome. However, the overall activity of the currently available conventional systemic treatments and the prognosis of patients with advanced or metastatic disease are still poor, making the treatment of this patient group challenging. Therefore, in a joint effort together with patient networks and organizations, namely Sarcoma Patients EuroNet (SPAEN), the international network of sarcoma patients organizations, and the National LeioMyo-Sarcoma Foundation (NLMSF) in the United States, we aim to summarize state-of-the-art treatments for leiomyosarcoma patients in order to identify knowledge gaps and current unmet needs, thereby guiding the community to design innovative clinical trials and basic research and close these research gaps. This position paper arose from a leiomyosarcoma research meeting in October 2020 hosted by the NLMSF and SPAEN.

Original languageEnglish (US)
Article number886
Pages (from-to)1-20
Number of pages20
JournalCancers
Volume13
Issue number4
DOIs
StatePublished - Feb 2 2021

Keywords

  • Leiomyosarcoma
  • NLMSF
  • Research
  • SPAEN
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Unmet medical needs and future perspectives for leiomyosarcoma patients—A position paper from the national leiomyosarcoma foundation (NLMSF) and sarcoma patients euronet (SPAEN)'. Together they form a unique fingerprint.

Cite this